Presence or Absence of Microbiome Modulates the Response of Mice Organism to Administered Drug Nabumetone
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00541275" target="_blank" >RIV/61388971:_____/20:00541275 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/20:73606544
Result on the web
<a href="https://www.biomed.cas.cz/physiolres/pdf/2020/69_S583.pdf" target="_blank" >https://www.biomed.cas.cz/physiolres/pdf/2020/69_S583.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.33549/physiolres.934607" target="_blank" >10.33549/physiolres.934607</a>
Alternative languages
Result language
angličtina
Original language name
Presence or Absence of Microbiome Modulates the Response of Mice Organism to Administered Drug Nabumetone
Original language description
The gut microbiota provides a wide range of beneficial functions for the host, and has an immense effect on the host's health status. The presence of microbiome in the gut may often influence the effect of an orally administered drug. Molecular mechanisms of this process are however mostly unclear. We investigated how the effect of a nonsteroidal drug nabumetone on expression of drug metabolizing enzymes (DMEs) in mice intestine and liver is changed by the presence of microbiota, here, using the germ free (GF) and specific pathogen free (SPF) BALB/c mice. First, we have found in a preliminary experiment that in the GF mice there is a tendency to increase bioavailability of the active form of nabumetone, which we have found now to be possibly influenced by differences in expression of DMEs in the GF and SPF mice. Indeed, we have observed that the expression of the most of selected cytochromes P450 (CYPs) was significantly changed in the small intestine of GF mice compared to the SPF ones. Moreover, orally administered nabumetone itself altered the expression of some CYPs and above all, in different ways in the GF and SPF mice. In the GF mice, the expression of the DMEs (CYP1A) responsible for the formation of active form of the drug are significantly increased in the small intestine and liver after nabumetone application. These results highlight the importance of gut microbiome in processes involved in drug metabolism in the both gastrointestinal tract and in the liver with possible clinical relevance.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Physiological Research
ISSN
0862-8408
e-ISSN
—
Volume of the periodical
69
Issue of the periodical within the volume
Suppl 4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
12
Pages from-to
583-594
UT code for WoS article
000621838200005
EID of the result in the Scopus database
2-s2.0-85102227413